NCT03510104View on ClinicalTrials.gov

Pharmacokinetic and Safety Study of MRX-2843 in Adults with Relapsed/Refractory Advanced And/or Metastatic Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 22, 2018

Primary Completion Date

February 28, 2025

Study Completion Date

April 30, 2025

Conditions
Advanced CancerMetastatic CancerNeoplasmsNeoplasm MetastasisNeoplastic ProcessesPathologic Processes
Interventions
DRUG

MRX-2843

MRX-2843 capsules

Trial Locations (2)

27514

Lineberger Comprehensive Cancer Center, Chapel Hill

30322

Emory University, Atlanta

All Listed Sponsors
lead

Meryx, Inc.

INDUSTRY